Traditional plasmid-based IVT template generation is slow, labor-intensive, and prone to sequence variability. Cell-free DNA synthesis now enables rapid, high-fidelity production of customized templates, cutting time and cost for mRNA design and optimization.

This innovation accelerates development of vaccines, protein and antibody therapies, cell therapies, and genome editing applications.

This study shows that Elegen’s ENFINIA IVT Ready DNA is a robust, efficient alternative to linearized plasmid templates. Across all tested parameters—DNA quality, mRNA yield, integrity, purity, and in-cell functionality (eGFP expression in HeLa cells)—IVT-ready linear DNA matched plasmid-derived performance.

Learn how ENFINIA IVT Ready DNA can overcome plasmid bottlenecks while maintaining full mRNA functionality.